Products for Research Use Only
RegisterLogin

AKI603

CAT: 0804-HY-123159-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123159-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC50 of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells[1][2].
CAS Number
1432515-73-5
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Aurora Kinase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/aki603.html
Purity
98.03
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=[N+]([O-])C1=CC=C(C=C1)NC2=NC(N3CCN(CC3)C)=CC(NC4=NNC(C)=C4)=N2
Molecular Formula
C19H23N9O2
Molecular Weight
409.45
Precautions
H315, H319, H320
References & Citations
[1]Le-Xun Wang, et al. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation. Sci Rep. 2016 Nov 8;6:35533.|[2]Fei-Meng Zheng, et al. A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance. Mol Cancer Ther. 2014 Aug;13 (8) :1991-2003.|[3]Zhenzhen Zhao, et al. Determination of a novel Aurora-A (AurA) kinase AKI603 by UPLC-MS/MS and its application to a bioavailability study in rat. J Pharm Biomed Anal. 2016 Jun 5;125:303-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A

Alternative Products

CatalogName
BA3728-25AKI603

Popular Products